These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21209626)

  • 61. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

  • 62. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.
    Hanaoka N; Jabri B; Dai Z; Ciszewski C; Stevens AM; Yee C; Nakakuma H; Spies T; Groh V
    J Immunol; 2010 Nov; 185(10):5732-42. PubMed ID: 20926796
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells.
    Massaia M; Attisano C; Peola S; Montacchini L; Omedé P; Corradini P; Ferrero D; Boccadoro M; Bianchi A; Pileri A
    Blood; 1993 Sep; 82(6):1787-97. PubMed ID: 8400233
    [TBL] [Abstract][Full Text] [Related]  

  • 64. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
    Fionda C; Soriani A; Zingoni A; Santoni A; Cippitelli M
    Biomed Res Int; 2015; 2015():178698. PubMed ID: 26161387
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
    Knight A; Mackinnon S; Lowdell MW
    Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Activation of V gamma 9V delta 2 T cells by NKG2D.
    Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
    J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
    Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
    Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.
    Huang H; Liu Y; Xiang J
    Cell Immunol; 2002; 217(1-2):12-22. PubMed ID: 12425997
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
    Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y
    J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
    Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
    Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
    [TBL] [Abstract][Full Text] [Related]  

  • 75. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
    Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
    J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
    [TBL] [Abstract][Full Text] [Related]  

  • 76. NKG2D and Its Ligand MULT1 Contribute to Disease Progression in a Mouse Model of Multiple Sclerosis.
    Legroux L; Moratalla AC; Laurent C; Deblois G; Verstraeten SL; Arbour N
    Front Immunol; 2019; 10():154. PubMed ID: 30787931
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
    Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
    [No Abstract]   [Full Text] [Related]  

  • 78. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.
    von Strandmann EP; Hansen HP; Reiners KS; Schnell R; Borchmann P; Merkert S; Simhadri VR; Draube A; Reiser M; Purr I; Hallek M; Engert A
    Blood; 2006 Mar; 107(5):1955-62. PubMed ID: 16210338
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
    Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
    Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.